Literature DB >> 18370531

Antidepressant prescribing patterns: a comparison of blacks and whites in a medicaid population.

D A Sclar1, L M Robison, T L Skaer, W M Dickson, C M Kozma, C E Reeder.   

Abstract

OBJECTIVE: This paper reports results stemming from a retrospective inquiry designed to determine the prescribing pattern of tricyclic antidepressants (TCAs) relative to selective serotonin reuptake inhibitors (SSRIs), and the subsequent effect on regimen adherence among African American (Black) and White beneficiaries enrolled in the state of South Carolina Medicaid programme. PATIENTS AND METHODS: Adjudicated patient-level paid-claims data for the time-frame 1 January 1990 to 31 December 1994 were abstracted resulting in a statewide cohort of 8596 ambulatory beneficiaries, 18 to 64 years of age, without receipt of antidepressant pharmacotherapy in the 1-year time-frame prior to initiating a regimen of either a TCA or SSRI, and remaining Medicaid-eligible for 1 year thereafter.
RESULTS: Black race [odds ratio (OR) = 1.56, 95% confidence interval (CI) = 1.43 to 1.70], age 40 to 64 years (OR = 1.15, 95% CI = 1.06 to 1.26), and male gender (OR = 1.27, 95% CI = 1.14 to 1.41) were significant predictors of initiating antidepressant pharmacotherapy with a TCA. Relative to Whites, Blacks were found to be less likely to have obtained at least a 3-month (>/=90 days) supply of a TCA (22.1 vs 31.7%) or an SSRI (30.7 vs 36.1%), or to have obtained a 6-month (>/=180 days) supply of a TCA (6.4 vs 10.9%) or an SSRI (8.1 vs 13.2%).
CONCLUSION: Further prospective research is required to discern the reasons for observed differences in prescribing and adherence patterns for antidepressant pharmacotherapy by age, gender and race, and to foster the development of educational programming designed to ensure clinically rational and equitable access to pharmacotherapeutic innovation.

Entities:  

Year:  1998        PMID: 18370531     DOI: 10.2165/00044011-199816020-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  45 in total

1.  The prevalence of major depression in black and white adults in five United States communities.

Authors:  P D Somervell; P J Leaf; M M Weissman; D G Blazer; M L Bruce
Journal:  Am J Epidemiol       Date:  1989-10       Impact factor: 4.897

Review 2.  Recent progress in the epidemiology of major depression.

Authors:  P W Burvill
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

3.  Medicare treatment differences for blacks and whites.

Authors:  A J Lee; S Gehlbach; M Reti; C S Baker
Journal:  Med Care       Date:  1997-12       Impact factor: 2.983

Review 4.  Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.

Authors:  B A Sproule; C A Naranjo; K E Brenmer; P C Hassan
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 5.  Lifetime risk of depression.

Authors:  H U Wittchen; B Knäuper; R C Kessler
Journal:  Br J Psychiatry Suppl       Date:  1994-12

Review 6.  Contemporary management of depression.

Authors:  J M Andrews; C B Nemeroff
Journal:  Am J Med       Date:  1994-12-19       Impact factor: 4.965

7.  Antidepressant use in the elderly: association with demographic characteristics, health-related factors, and health care utilization.

Authors:  S L Brown; M E Salive; J M Guralnik; M Pahor; D P Chapman; D Blazer
Journal:  J Clin Epidemiol       Date:  1995-03       Impact factor: 6.437

Review 8.  A practical approach to the management of depression.

Authors:  H L Lim
Journal:  Singapore Med J       Date:  1993-10       Impact factor: 1.858

Review 9.  Race, racism, and epidemiological surveys.

Authors:  V R Adebimpe
Journal:  Hosp Community Psychiatry       Date:  1994-01

10.  The effect of gender and race on the measurement properties of the CES-D in older adults.

Authors:  C M Callahan; F D Wolinsky
Journal:  Med Care       Date:  1994-04       Impact factor: 2.983

View more
  6 in total

1.  Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS).

Authors:  Joel F Farley; Richard R Cline; Kiran Gupta
Journal:  Osteoporos Int       Date:  2005-11-29       Impact factor: 4.507

2.  Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.

Authors:  Rahn K Bailey; Craig H Mallinckrodt; Madelaine M Wohlreich; John G Watkin; John M Plewes
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

Review 3.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

4.  Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race?

Authors:  David A Sclar; Linda M Robison; Jennifer M Schmidt; Kurt A Bowen; Leigh V Castillo; Ambartsum M Oganov
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

5.  Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  Sociol Focus       Date:  2009

6.  Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study.

Authors:  Murat Beyazyüz; Yakup Albayrak; Oğuzhan Bekir Eğilmez; Neslihan Albayrak; Elmas Beyazyüz
Journal:  Psychiatry Investig       Date:  2013-05-30       Impact factor: 2.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.